NCT06397027View on ClinicalTrials.gov

A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias

PHASE1RecruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

December 27, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

December 31, 2030

Conditions
Refractory Acute LeukemiaPediatric Relapsed
Interventions
DRUG

Ziftomenib

Given by IV

DRUG

Venetoclax

Given by PO

DRUG

Azacitidine

Given by PO

Trial Locations (1)

77030

RECRUITING

MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Kura Oncology, Inc.
All Listed Sponsors
collaborator

Kura Oncology, Inc.

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT06397027 - A Phase I Study Investigating the Combination of the Ziftomenib, Venetoclax and Azacitidine in Pediatric Relapsed and Refractory Acute Leukemias | Biotech Hunter | Biotech Hunter